Arcturus Therapeutics Holdings Inc. (ARCT) stock
ARCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/303% below fair value
$8.36−0.08 (-0.95%)
Close on Nov 13, 2026Market cap $237.62MP/E –Yield –
Arcturus Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Arcturus Therapeutics's profit margin for the twelve months ending Sep 30, 2026 was -285.9%. For fiscal 2025 it was -80.2%, against -53.1% the year before. The highest annual figure on record is 4.5% in fiscal 2022.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -80.2% | −27.1 |
| FY2024 | Dec 31, 2024 | -53.1% | −35.3 |
| FY2023 | Dec 31, 2023 | -17.8% | −22.4 |
| FY2022 | Dec 31, 2022 | 4.5% | +1652.5 |
| FY2021 | Dec 31, 2021 | -1648.0% | −891.6 |
| FY2020 | Dec 31, 2020 | -756.3% | −631.3 |
| FY2019 | Dec 31, 2019 | -125.0% | +13.3 |
| FY2018 | Dec 31, 2018 | -138.3% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -40.5% | +37.9 |
| Q2 FY2026 | Jun 30, 2026 | -803.8% | −771.4 |
| Q1 FY2026 | Mar 31, 2026 | -1308.3% | −1260.4 |
| Q4 FY2025 | Dec 31, 2025 | -404.1% | −272.3 |
| Q3 FY2025 | Sep 30, 2025 | -78.4% | −61.8 |
| Q2 FY2025 | Jun 30, 2025 | -32.4% | +2.1 |
| Q1 FY2025 | Mar 31, 2025 | -47.9% | +22.6 |
| Q4 FY2024 | Dec 31, 2024 | -131.8% | −93.9 |
| Q3 FY2024 | Sep 30, 2024 | -16.6% | +19.4 |
| Q2 FY2024 | Jun 30, 2024 | -34.5% | +465.0 |
| Q1 FY2024 | Mar 31, 2024 | -70.5% | −133.8 |
| Q4 FY2023 | Dec 31, 2023 | -37.9% | −111.1 |
| Q3 FY2023 | Sep 30, 2023 | -35.9% | +227.9 |
| Q2 FY2023 | Jun 30, 2023 | -499.6% | −420.0 |
| Q1 FY2023 | Mar 31, 2023 | 63.2% | +1039.0 |
| Q4 FY2022 | Dec 31, 2022 | 73.2% | +740.5 |
| Q3 FY2022 | Sep 30, 2022 | -263.8% | +1955.5 |
| Q2 FY2022 | Jun 30, 2022 | -79.6% | +2648.1 |
| Q1 FY2022 | Mar 31, 2022 | -975.8% | +1673.3 |
| Q4 FY2021 | Dec 31, 2021 | -667.3% | +722.5 |
| Q3 FY2021 | Sep 30, 2021 | -2219.3% | −1319.0 |
| Q2 FY2021 | Jun 30, 2021 | -2727.7% | −2285.7 |
| Q1 FY2021 | Mar 31, 2021 | -2649.1% | −2279.6 |
| Q4 FY2020 | Dec 31, 2020 | -1389.8% | −1019.6 |
| Q3 FY2020 | Sep 30, 2020 | -900.3% | −676.3 |
| Q2 FY2020 | Jun 30, 2020 | -442.0% | −435.2 |
| Q1 FY2020 | Mar 31, 2020 | -369.5% | −211.2 |
| Q4 FY2019 | Dec 31, 2019 | -370.2% | −356.9 |
| Q3 FY2019 | Sep 30, 2019 | -224.0% | −99.8 |
| Q2 FY2019 | Jun 30, 2019 | -6.7% | +410.3 |
| Q1 FY2019 | Mar 31, 2019 | -158.3% | – |
| Q4 FY2018 | Dec 31, 2018 | -13.3% | – |
| Q3 FY2018 | Sep 30, 2018 | -124.2% | – |
| Q2 FY2018 | Jun 30, 2018 | -417.0% | – |
See a number that looks wrong?